Y-90 radioembolization offers promise for late-stage liver cancer

Dec 14, 2010

The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.

The glass spheres contain a radioactive element, yttrium-90, more commonly known as Y-90, which emits radiation for a very limited distance so that healthy tissue around the tumor remains unaffected. (2.5mm or less than 1/16th inch in soft tissue).

Y-90 microsphere radioembolization is an FDA-approved procedure first used in the United States in 2002. The outpatient procedure has gained favor with interventional radiologists for treating a type of cancer that is becoming more prevalent due to an increase in the cases of hepatitis and obesity, which along with alcoholism are the three primary causes of .

Daniel E. Wertman Jr., M.D., co-director of vascular and interventional radiology and assistant professor of clinical radiology at the Indiana University School of Medicine, said more than 300 patients have been treated with Y-90 radioembolization since the program was initiated at Indiana University Hospital and the Indiana University Melvin and Bren Simon Cancer Center more than 3 years ago.

"I'm really excited about the treatment," said Dr. Wertman. "I think it's probably the best thing that has happened in our specialty."

His colleague, Matthew S. Johnson, M.D., professor of radiology and surgery at IU, reports very positive results with critically ill patients undergoing the treatment. Forty percent of his patients treated with radioembolization had tumors shrink or remain stable at three months. This is exceptional news since patients with advanced liver cancer have few options, he explained.

"I am not aiming for a cure, I'm aiming to extend their lives and make them feel better," said Dr. Johnson.

Physicians agree that liver cancer is a very complex disease. "With the Y-90 radioembolization, the disease can be address with a minimally invasive treatment and through a little band-aid sized incision we can solve very complicated problems," said Dr. Wertman.

A catheter is inserted through a tiny incision in the groin and threaded through the arteries until it reaches the hepatic artery, one of two blood vessels feeding the liver.

The physiology of the liver makes it an ideal organ for this type of treatment. The hepatic artery is the one that most commonly supplies blood to the cancerous tumors.

When the catheter is in the proper place, millions of the microscopic beads containing Y-90 are released. The microspheres lodge in the smaller vessels that directly feed the tumor, stopping blood flow and emitting radiation to kill the tumor cells.

Patients need not be isolated after treatment with Y-90 and usually are released about three hours after the treatment.

What Y-90 offers, Dr. Johnson said, is optimism. "Hope is a magical thing."

Explore further: Team identifies source of most cases of invasive bladder cancer

Provided by Indiana University School of Medicine

3.7 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Cancer stem cells linked to drug resistance

17 hours ago

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments : 3

Adjust slider to filter visible comments by rank

Display comments: newest first

fixer
1 / 5 (1) Dec 15, 2010
"I am not aiming for a cure, I'm aiming to extend their lives and make them feel better," said Dr. Johnson.

At several thousand dollars a shot to live a few extra weeks in agony it gets no kudos from me, I have a good friend who emptied her bank account on this as a trial patient to little effect.

"What Y-90 offers, Dr. Johnson said, is optimism. "Hope is a magical thing.""

It certainly is to cancer researchers, its more profitable than religion and about as useful.
Still, at least it's honest, it doesn't claim to do any good at all for 60% of patients and offers only 3+ months for the other 40%.
frajo
not rated yet Dec 19, 2010
It's statistics. Population 300, 120 of them had a mean survival time of 3 months. We don't know the distribution but depending on the individual case there are some patients who survived considerably longer than three months.
When the treatment is done before the patients become critically ill the outcomes will be even better.

And would you refuse the chance of living three more months if you have reached the critically ill stage?
fixer
not rated yet Dec 23, 2010
No I wouldn't, but I would prefer to spend my cash on somthing that offered a chance of survival for longer than 3 months.
I wouldn't waste a cent on this!

More news stories

Cancer stem cells linked to drug resistance

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Finnish inventor rethinks design of the axe

(Phys.org) —Finnish inventor Heikki Kärnä is the man behind the Vipukirves Leveraxe, which is a precision tool for splitting firewood. He designed the tool to make the job easier and more efficient, with ...

Poll: Big Bang a big question for most Americans

Few Americans question that smoking causes cancer. But they have more skepticism than confidence in global warming, the age of the Earth and evolution and have the most trouble believing a Big Bang created the universe 13.8 ...